Emerging role of tacrolimus in the treatment of atopic dermatitis: Recent advances

Takeshi Nakahara, Hiroshi Morimoto, Naofumi Murakami, Masutaka Furue

研究成果: ジャーナルへの寄稿評論記事

抄録

More than fifteen years have passed since the approval of clinical use of tacrolimus ointment for atopic dermatitis. Its efficacy and safety have been demonstrated clearly in many global and domestic short-term and long-term administration trials. Although prolonged external application of steroid causes adverse reactions including cutaneous atrophy, tacrolimus ointment does not cause such adverse reaction. Therefore, tacrolimus has been positioned as a drug that exerts therapeutic effects of external steroid but causes none of its unwanted side-effects. The pathological condition of atopic dermatitis has not been fully understood. However, the genetic, physiological and immunological findings and the therapeutic findings based on the use of new drugs have been accumulating and many scientific advancements have been achieved. With progress in understanding of the pathological condition, the possibility has been suggested that tacrolimus, which was clinically applied originally as an immunosuppressant for control of T cell activation, may control various aspects of the development/pathological condition of atopic dermatitis. In this paper, we summarized the recent findings on tacrolimus including control of itching, inhibition of allergic inflammation and improvement of skin barrier function and addressed the new possibility of treatment of atopic dermatitis with tacrolimus ointment.

元の言語英語
ページ(範囲)468-474
ページ数7
ジャーナルNishinihon Journal of Dermatology
78
発行部数5
出版物ステータス出版済み - 1 1 2016

Fingerprint

Tacrolimus
Atopic Dermatitis
Ointments
Steroids
Skin
Therapeutic Uses
Pruritus
Immunosuppressive Agents
Pharmaceutical Preparations
Atrophy
Inflammation
T-Lymphocytes
Safety

All Science Journal Classification (ASJC) codes

  • Dermatology

これを引用

Emerging role of tacrolimus in the treatment of atopic dermatitis : Recent advances. / Nakahara, Takeshi; Morimoto, Hiroshi; Murakami, Naofumi; Furue, Masutaka.

:: Nishinihon Journal of Dermatology, 巻 78, 番号 5, 01.01.2016, p. 468-474.

研究成果: ジャーナルへの寄稿評論記事

@article{31a1ec1a22de47a5890d5970508d5e6d,
title = "Emerging role of tacrolimus in the treatment of atopic dermatitis: Recent advances",
abstract = "More than fifteen years have passed since the approval of clinical use of tacrolimus ointment for atopic dermatitis. Its efficacy and safety have been demonstrated clearly in many global and domestic short-term and long-term administration trials. Although prolonged external application of steroid causes adverse reactions including cutaneous atrophy, tacrolimus ointment does not cause such adverse reaction. Therefore, tacrolimus has been positioned as a drug that exerts therapeutic effects of external steroid but causes none of its unwanted side-effects. The pathological condition of atopic dermatitis has not been fully understood. However, the genetic, physiological and immunological findings and the therapeutic findings based on the use of new drugs have been accumulating and many scientific advancements have been achieved. With progress in understanding of the pathological condition, the possibility has been suggested that tacrolimus, which was clinically applied originally as an immunosuppressant for control of T cell activation, may control various aspects of the development/pathological condition of atopic dermatitis. In this paper, we summarized the recent findings on tacrolimus including control of itching, inhibition of allergic inflammation and improvement of skin barrier function and addressed the new possibility of treatment of atopic dermatitis with tacrolimus ointment.",
author = "Takeshi Nakahara and Hiroshi Morimoto and Naofumi Murakami and Masutaka Furue",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "78",
pages = "468--474",
journal = "Nishinihon Journal of Dermatology",
issn = "0386-9784",
publisher = "Kyushu University, Faculty of Science",
number = "5",

}

TY - JOUR

T1 - Emerging role of tacrolimus in the treatment of atopic dermatitis

T2 - Recent advances

AU - Nakahara, Takeshi

AU - Morimoto, Hiroshi

AU - Murakami, Naofumi

AU - Furue, Masutaka

PY - 2016/1/1

Y1 - 2016/1/1

N2 - More than fifteen years have passed since the approval of clinical use of tacrolimus ointment for atopic dermatitis. Its efficacy and safety have been demonstrated clearly in many global and domestic short-term and long-term administration trials. Although prolonged external application of steroid causes adverse reactions including cutaneous atrophy, tacrolimus ointment does not cause such adverse reaction. Therefore, tacrolimus has been positioned as a drug that exerts therapeutic effects of external steroid but causes none of its unwanted side-effects. The pathological condition of atopic dermatitis has not been fully understood. However, the genetic, physiological and immunological findings and the therapeutic findings based on the use of new drugs have been accumulating and many scientific advancements have been achieved. With progress in understanding of the pathological condition, the possibility has been suggested that tacrolimus, which was clinically applied originally as an immunosuppressant for control of T cell activation, may control various aspects of the development/pathological condition of atopic dermatitis. In this paper, we summarized the recent findings on tacrolimus including control of itching, inhibition of allergic inflammation and improvement of skin barrier function and addressed the new possibility of treatment of atopic dermatitis with tacrolimus ointment.

AB - More than fifteen years have passed since the approval of clinical use of tacrolimus ointment for atopic dermatitis. Its efficacy and safety have been demonstrated clearly in many global and domestic short-term and long-term administration trials. Although prolonged external application of steroid causes adverse reactions including cutaneous atrophy, tacrolimus ointment does not cause such adverse reaction. Therefore, tacrolimus has been positioned as a drug that exerts therapeutic effects of external steroid but causes none of its unwanted side-effects. The pathological condition of atopic dermatitis has not been fully understood. However, the genetic, physiological and immunological findings and the therapeutic findings based on the use of new drugs have been accumulating and many scientific advancements have been achieved. With progress in understanding of the pathological condition, the possibility has been suggested that tacrolimus, which was clinically applied originally as an immunosuppressant for control of T cell activation, may control various aspects of the development/pathological condition of atopic dermatitis. In this paper, we summarized the recent findings on tacrolimus including control of itching, inhibition of allergic inflammation and improvement of skin barrier function and addressed the new possibility of treatment of atopic dermatitis with tacrolimus ointment.

UR - http://www.scopus.com/inward/record.url?scp=85014223810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014223810&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:85014223810

VL - 78

SP - 468

EP - 474

JO - Nishinihon Journal of Dermatology

JF - Nishinihon Journal of Dermatology

SN - 0386-9784

IS - 5

ER -